Table 3.
Impact of concomitant peripheral arthritis on patient-reported outcomes and days of sick leave during the 5-year follow-up period in patients with recent onset axial spondyloarthritis
| Any arthritis n = 255 mean (SD)* |
No arthritis n = 453 mean (SD) |
Crude p value | p value adjusted for TNFb | p value adjusted for csDMARDs | |
|---|---|---|---|---|---|
| BASDAI | 40.46 (22.6) | 34.30 (20.7) | < 0.001 | 0.001 | < 0.001 |
| BASFI | 27.89 (23.2) | 22.52 (21.0) | 0.001 | 0.049 | 0.011 |
| SF36-MCS | 42.17 (11.7) | 43.99 (11.0) | 0.003 | 0.059 | 0.022 |
| SF36-PCS | 40.93 (9.65) | 43.09 (9.19) | < 0.001 | 0.056 | 0.015 |
| Days of sick leave | 17.97 (57.5) | 12.78 (47.2) | 0.024 | 0.451 | 0.143 |
p value for mixed model with random effects. All results are presented as mean and standard deviation
*Mean value observed over time
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, csDMARDs synthetic disease-modifying anti-rheumatic drugs, SF36-MCS mental component of the SF36 questionnaire, SF36-PCS physical component of the SF36 questionnaire, TNFb tumour necrosis factor blockers